FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 09/2021”.

The Monitor is a month-to-month printed overview of enterprise capital traits within the European Life Sciences sector.

As of the top of September 2021 we determine the next present VC traits in Europe:

  • In 2021, total Life Sciences funding has reached EUR 9,955m to this point
  • High 5 Offers exceed EUR 190m every, largest transaction amounted to EUR 497m in CMR Surgical Ltd. (United Kingdom)
  • BlackRock (USA) nonetheless dominates the High 5 Buyers (by deal quantity), adopted by Constancy Administration & Analysis (USA) and Novo Holdings (Denmark)
  • The Biotechnology sector acquired 43% of the full funding quantity (-7% factors in comparison with the earlier month)
  • Oncology dominates as the highest indication

To entry the total report, please click on right here.

By Dr. Mathias Schott, Sebastian Sommer and Alexander Kuhn

Leave a Reply

Your email address will not be published.